Part 5/12:
Despite the commendable growth in subscriber numbers and revenue, Hims has faced significant stock price volatility. The stock soared to nearly $70 a share but fell sharply by approximately 50%, settling around $36. This steep decline has been largely attributed to investor reactions to guidance revisions and uncertainties regarding the glp-1 market dynamics following the FDA's resolution of semaglutide shortages, which had previously inflated demand for Hims’ compounded versions.